TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01059500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Webtool
Description: Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP \>5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP\>20% consider empiric anticoagulation with heparin if no contraindications.
Study: NCT04116008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT03162068

Intervention type: OTHER
Intervention: Osteodensitometry and pQCT
Description: The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.

Intervention type: OTHER
Intervention: Osteodensitometry and pQCT
Description: The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.

Intervention type: OTHER
Intervention: Osteodensitometry and pQCT
Description: The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
Study: NCT01080092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing technique
Description: breathing technique as a stress management technique, reinforced by biofeedback
Study: NCT00737503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine (ROTARIX)
Description: Rotavirus Vaccine two doses four weeks apart
Study: NCT01661205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation procedure staged catheter ablation
Description: AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
Study: NCT04358718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with epidural analgesia
Description: Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
Study: NCT02963948

Intervention type: BEHAVIORAL
Intervention: Meetings with implementation leader(s)
Description: The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
Study: NCT01080092

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral strategies
Description: the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
Study: NCT00806208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.012 mg/kg MEDI 507 and Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.04 mg/kg MEDI 507 and Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.12 mg/kg MEDI 507 and Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.4 mg/kg MEDI 507 and Methylprednisolone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (alternative) study days 0, 3,6, and 9
Study: NCT04168255

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double tamponade
Description: Double tamponade procedure in retinal detachment with PVR and inferior breaks
Study: NCT00070564

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT02044003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovasc Tack Intravascular Staple System (Tack)
Description: Tack-It Dissection repair
Study: NCT00624689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified formula (MFGM-enriched formula with reduced energy and protein content)
Description: MFGM-enriched formula with reduced energy and protein content
Study: NCT03077607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 100 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg oral dose
Study: NCT02455453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FFNP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTI/Siemens Biograph 40 PET/CT Scanner
Description: * Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Study: NCT04141397

Intervention type: GENETIC
Intervention: Initiation of POG-related WGTA
Description: POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.

Intervention type: GENETIC
Intervention: Usual care
Description: Usual care, not involving the initiation of POG-related WGTA
Study: NCT00368459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: Raloxifene is a selective estrogen receptor modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo
Study: NCT02794688

Intervention type: PROCEDURE
Intervention: Ductal lavage therapy
Description: 1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (\>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed.
Study: NCT01515098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried blueberries
Description: Wild blueberries, freeze-dried and pulverized

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Placebo
Description: Placebo developed to closely match blueberry powder.
Study: NCT03472937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter placement for cervical ripening
Description: Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter placement for cervical ripening
Description: Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
Study: NCT05386290

Intervention type: DRUG
Intervention: Infliximab
Description: A TNFα inhibitor in UC and CD treatment

Intervention type: DRUG
Intervention: Infliximab
Description: A TNFα inhibitor in UC and CD treatment

Intervention type: DRUG
Intervention: Vedolizumab
Description: An integrin receptor antagonist in UC and CD treatment

Intervention type: DRUG
Intervention: Ustekinumab
Description: An IL-12/IL-23 inhibitor in CD treatment

Intervention type: DRUG
Intervention: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)
Description: Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).

Intervention type: DRUG
Intervention: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)
Description: Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
Study: NCT00893074

Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 30mg/day
Description: 10mg dronabinol administered 3x/day for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 60mg/day
Description: 20mg dronabinol administered 3x/day for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Dronabinol 120mg/day
Description: 40mg dronabinol administered 3x/day for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo dronabinol administered 3x/day for 5 days
Study: NCT04957212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: An initial dose of 840 mg, followed by 420 mg every 3-weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: An initial dose of 840 mg, followed by 420 mg every 3-weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 every 3-weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 every 3-weeks
Study: NCT04233242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical management informed by HIV-1 genotypic resistance testing
Description: The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support.
Study: NCT02785562

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of PDL1 expression
Description: Intervention : 2 biopsy slides will be analyzed in central laboratory.
Study: NCT02318615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Axillary Plasty
Description: Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
Study: NCT01939353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN SR
Description: CTN SR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CTN SR-matching placebo tablets
Study: NCT02397551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: Given in different doses and timing to support the luteal phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: Given in different doses and timing to support the luteal phase
Study: NCT00527761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: 150 mg by mouth (PO) on Days 1 - 5.
Study: NCT00387244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision for Spinal Cord Stimulation
Description: Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
Study: NCT01730378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prepandrix™
Description: 2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 1 dose administered intramuscularly in the deltoid region of non-dominant arm.
Study: NCT02983175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound assessment of gastric content
Description: Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA.
Study: NCT03909737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to pregnant women
Description: Azithromycin to pregnant women at antenatal care visits and during delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to pregnant women
Description: Azithromycin to pregnant women at antenatal care visits and during delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to infants
Description: Azithromycin to infants at 6 and 14 week EPI visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to infants
Description: Azithromycin to infants at 6 and 14 week EPI visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin to infants
Description: Azithromycin to infants at 6 and 14 week EPI visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to pregnant women
Description: Placebo to pregnant women at antenatal care visits and during delivery
Study: NCT00955708

Intervention type: DEVICE
Intervention: ACUITY Spiral Left Ventricular Lead
Description: The implant of the ACUITY Spiral Lead
Study: NCT00514579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood transplantation
Description: Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
Study: NCT01405651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 30 mg, 100 mg, 300 mg at multiple doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-6950
Description: Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
Study: NCT02002962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A injection
Study: NCT04723290

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological tests for SARS Cov-2
Description: Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
Study: NCT01991327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03296800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin 20 mg, tablet; qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin 20 mg, tablet; qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin 20 mg, tablet; qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid tablets, 500 mg; bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin, 600 mg (2 x 300 mg capsules); qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil hydrochloride tablet, 120 mg; qd
Study: NCT05977205

Intervention type: OTHER
Intervention: No interventions, observational study
Description: Not applicable, no interventions, observational study

Intervention type: OTHER
Intervention: No interventions, observational study
Description: Not applicable, no interventions, observational study

Intervention type: OTHER
Intervention: No interventions, observational study
Description: Not applicable, no interventions, observational study
Study: NCT00737477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.